Advanced search
Log in
Log in
Or log in with
GoogleGoogle
Twitter Twitter
Facebook Facebook
Apple Apple     
Sign up
Email Registration
Or log in with
GoogleGoogle
Twitter Twitter
Facebook Facebook
Apple Apple     
  1. Homepage
  2. Equities
  3. United States
  4. Nasdaq
  5. Ascendis Pharma A/S
  6. Consensus
    ASND   US04351P1012

ASCENDIS PHARMA A/S

(ASND)
  Report
Delayed Nasdaq  -  04:00:01 2023-02-07 pm EST
116.35 USD   +1.93%
08:01aAscendis Pharma Announces Full Year 2022 Financial Results and Business Update Conference Call on February 16
AQ
01/18Tech Stocks Lead European Equities Modestly Higher in Wednesday Trading
MT
01/17Pharma Stocks Lead European Equities Higher in Tuesday Trading
MT
SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisionsFunds 
Evolution of the average Target Price on ASCENDIS PHARMA A/S
Target Price consensus revisions : last 18 months
Recommendations (Chart) ASCENDIS PHARMA A/S
Analyst Recommendations on ASCENDIS PHARMA A/S
01/17SVB Securities Adjusts Price Target on Ascendis Pharma to $163 From $148, Maintains Outper..
MT
01/03Wells Fargo Boosts Price Target on Ascendis Pharma to $177 From $169, Keeps Overweight Rat..
MT
2022Morgan Stanley Adjusts Price Target on Ascendis Pharma to $148 From $146, Maintains Overwe..
MT
2022Wedbush Raises Price Target on Ascendis Pharma to $164 From $151, Keeps Outperform Rating
MT
2022Wells Fargo Adjusts Price Target on Ascendis Pharma to $169 From $172, Maintains Overweigh..
MT
2022Citigroup Adjusts Price Target on Ascendis Pharma A/S to $163 From $157, Maintains Buy Rat..
MT
2022Credit Suisse Adjusts Ascendis Pharma's Price Target to $130 From $123, Keeps Outperform R..
MT
More recommendations
Consensus
Sell
Buy
Mean consensus BUY
Number of Analysts 14
Last Close Price 108,79 €
Average target price 146,52 €
Spread / Average Target 34,7%
High Price Target 171,48 €
Spread / Highest target 57,6%
Low Price Target 88,26 €
Spread / Lowest Target -18,9%
Consensus detail
Consensus revision (last 18 months)